SCHEMBL2073307

SCHEMBL2073307

CC(C)n1cc(-c2ccc(Oc3ccc(C=O)cc3)cc2)c2c(N)ncnc21

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TEK Q02763 17/20 0.76
KDR P35968 16/20 0.76
LCK P06239 15/20 0.76
SRC P12931 6/20 0.76
PIK3CD O00329 1/20 0.53
PIK3CA P42336 1/20 0.53
PIK3CB P42338 1/20 0.53
PIK3CG P48736 1/20 0.53
PRKDC P78527 1/20 0.53
HCK P08631 1/20 0.48
KDM4E B2RXH2 1/20 0.47
MEN1 O00255 1/20 0.47
RGS12 O14924 1/20 0.47
NPC1 O15118 1/20 0.47
GMNN O75496 1/20 0.47
ALDH1A1 P00352 1/20 0.47
EGFR P00533 1/20 0.47
LMNA P02545 1/20 0.47
TP53 P04637 1/20 0.47
CYP1A2 P05177 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2074938 0.93 KDR (0.64) TEKKDRLCKSRCPIK3CD
SCHEMBL2075162 0.88 KDR (0.63) TEKKDRLCKSRCPIK3CD
SCHEMBL7005359 0.86 TEK (1.00) TEKKDRLCKSRCPIK3CD
SCHEMBL29552512 0.86 TEK (1.00) TEKKDRLCKSRCPIK3CD
SCHEMBL7011622 0.85 TEK (0.81) TEKKDRLCKSRCPIK3CD
SCHEMBL2076046 0.85 KDR (0.60) TEKKDRLCKSRCPIK3CD
SCHEMBL2075758 0.85 KDR (0.76) TEKKDRLCKSRCPIK3CD
SCHEMBL7853816 0.84 TEK (0.79) TEKKDRLCKSRCPIK3CD
SCHEMBL2073278 0.84 KDR (0.66) TEKKDRLCKSRCPIK3CD
SCHEMBL2074967 0.84 KDR (0.84) TEKKDRLCKSRCPIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7863444-B2 4-aminopyrrolopyrimidines as kinase inhibitors ABBOTT LABORATORIES (US) 2011-01-04 US disclosed
US-20050008640-A1 Method of treating transplant rejection ABBOTT LABORATORIES 2005-01-13 US disclosed
US-20030187001-A1 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2003-10-02 US disclosed
EP-1114052-A1 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS BASF AKTIENGESELLSCHAFT (DE) 2001-07-11 EP disclosed
WO-2000017202-A1 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS BASF AKTIENGESELLSCHAFT (DE) 2000-03-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050008640-A1 Method of treating transplant rejection LCK, ZAP70, FYN TEK 1465/4885KDR 3981/4885LCK 1/4885
US-20030187001-A1 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS LCK, PPP5C, DUSP1 TEK 199/4885KDR 140/4885LCK 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.